Document Detail

Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model.
MedLine Citation:
PMID:  9039606     Owner:  NLM     Status:  MEDLINE    
This work was conducted to test the hypothesis that contrast-enhanced MRI with hepatocyte-specific contrast agents facilitates quantitation and mapping of diffuse liver diseases such as hepatitis and cirrhosis. Gadobenate dimeglumine (Gd-BOPTA/Dimeg, Bracco SpA, Millano, Italy) is a new paramagnetic hepatocyte-specific contrast agent currently undergoing clinical trials. We have assessed the usefulness of gadobenate dimeglumine for the diagnosis of diffuse liver diseases in a rat model of chemically induced hepatitis. The study was based on the measurements of in vivo liver relaxation times as well as on the acquisition of standard SE images. Acute hepatitis considerably reduced the degree of T1 shortening of liver parenchyma caused by intravenous injection of .25 mmol/kg of gadobenate dimeglumine. Analogously, the enhancement of the MRI signal intensity of the liver of rats with hepatitis observed in T1-weighted spin-echo (SE) images was inferior, in terms of both strength and duration, to that recorded in control rats at doses of .25 mmol/kg and .075 mmol/kg of gadobenate dimeglumine. Our results show that gadobenate dimeglumine-enhanced MR imaging has the potential for visualization of hepatitis and for assessment of liver function. Our conclusions differ from those previously published on this subject by other authors. The reasons that led to differing conclusions are discussed.
P Marzola; F Maggioni; E Vicinanza; M Daprà; F M Cavagna
Related Documents :
8516566 - Altered energy metabolism and oxidative injury following endotoxemia in rats with norma...
16480686 - Reactive oxygen species modify oligosaccharides of glycoproteins in vivo: a study of a ...
1019256 - Effect of the hepatocarcinogen ethionine on hepatic messenger rna synthesis.
8605226 - Visualization of yellowish-orange luminescence from cuprous metallothioneins in liver o...
17984286 - Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic ...
6477946 - Hyperlipidemia in tumor-bearing rats.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of magnetic resonance imaging : JMRI     Volume:  7     ISSN:  1053-1807     ISO Abbreviation:  J Magn Reson Imaging     Publication Date:    1997 Jan-Feb
Date Detail:
Created Date:  1997-05-08     Completed Date:  1997-05-08     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  9105850     Medline TA:  J Magn Reson Imaging     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  147-52     Citation Subset:  IM    
Milano Research Centre, Bracco SpA, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Contrast Media*
Disease Models, Animal
Hepatitis, Animal / diagnosis*
Image Enhancement / methods
Infusions, Intravenous
Liver / pathology
Magnetic Resonance Imaging / methods*
Meglumine / administration & dosage,  analogs & derivatives*,  diagnostic use
Organometallic Compounds / administration & dosage,  diagnostic use*
Rats, Sprague-Dawley
Reference Values
Sensitivity and Specificity
Reg. No./Substance:
0/Contrast Media; 0/Organometallic Compounds; 113662-23-0/gadobenic acid; 6284-40-8/Meglumine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  MR imaging of the liver: effect of portal hypertension on hepatic parenchymal enhancement using a ga...
Next Document:  Ampullary carcinoma: demonstration by current MR techniques.